Eli Lilly and Company has partnered with Indiana University in a five-year agreement worth up to $40 million to bolster clinical trials and advance research. This collaboration, the largest single industry-sponsored agreement in the university's history, will focus on accelerating the development of new treatments for Alzheimer's disease, diabetes, and cancer. The partnership aims to improve clinical trial infrastructure and patient recruitment, partly by utilizing artificial intelligence. It will also work to expand neuroscience research, with an initial focus on Alzheimer's, and develop life science talent in Indiana. No significant market reaction to this announcement was noted in the available reports.